| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Crescita Therapeutics Inc (TO: CTX)
CTX Technical Analysis
2
| As on 21st Nov 2024 CTX STOCK Price closed @ 0.62 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.55 & Strong Sell for SHORT-TERM with Stoploss of 0.68 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CTXSTOCK Price
| Open | 0.60 | Change | Price | % |
| High | 0.62 | 1 Day | 0.04 | 6.90 |
| Low | 0.60 | 1 Week | 0.04 | 6.90 |
| Close | 0.62 | 1 Month | 0.02 | 3.33 |
| Volume | 2786 | 1 Year | -0.03 | -4.62 |
| 52 Week High 0.73 | 52 Week Low 0.36 | ||||
TO Canada Most Active Stocks
| YRI | 7.89 | 0.13% |
| ENB | 60.79 | 1.40% |
| CNQ | 48.30 | 2.31% |
| MFC | 45.33 | -1.56% |
| UEX | 0.50 | 16.28% |
| SU | 57.21 | 0.02% |
| CVE | 22.64 | 0.98% |
| SJR-B | 40.48 | 0.02% |
| AC | 23.97 | -2.16% |
| BCE | 37.27 | -1.25% |
TO Canada Top Gainers Stocks
TO Canada Top Losers Stocks
| CTX Daily Charts |
CTX Intraday Charts |
Whats New @ Bazaartrend |
CTX Free Analysis |
|
|
CTX Important Levels Intraday
| RESISTANCE | 0.66 |
| RESISTANCE | 0.65 |
| RESISTANCE | 0.64 |
| RESISTANCE | 0.63 |
| SUPPORT | 0.61 |
| SUPPORT | 0.60 |
| SUPPORT | 0.59 |
| SUPPORT | 0.58 |
CTX Forecast November 2024
| 4th UP Forecast | 0.77 |
| 3rd UP Forecast | 0.72 |
| 2nd UP Forecast | 0.69 |
| 1st UP Forecast | 0.66 |
| 1st DOWN Forecast | 0.58 |
| 2nd DOWN Forecast | 0.55 |
| 3rd DOWN Forecast | 0.52 |
| 4th DOWN Forecast | 0.47 |
CTX Weekly Forecast
| 4th UP Forecast | 0.66 |
| 3rd UP Forecast | 0.65 |
| 2nd UP Forecast | 0.64 |
| 1st UP Forecast | 0.63 |
| 1st DOWN Forecast | 0.61 |
| 2nd DOWN Forecast | 0.60 |
| 3rd DOWN Forecast | 0.59 |
| 4th DOWN Forecast | 0.58 |
CTX Forecast2024
| 4th UP Forecast | 1.33 |
| 3rd UP Forecast | 1.1 |
| 2nd UP Forecast | 0.96 |
| 1st UP Forecast | 0.82 |
| 1st DOWN Forecast | 0.42 |
| 2nd DOWN Forecast | 0.28 |
| 3rd DOWN Forecast | 0.14 |
| 4th DOWN Forecast | -0.09 |
Crescita Therapeutics Inc ( TO Canada Symbol : CTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CTX Business Profile
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns various proprietary drug delivery platforms, including Peel, DuraPeel, and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; and CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; skincare products primarily for the Asian consumers under Dermazulene brand; and a line of products to target and treat various skincare concerns under the Alyria brand. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis and hemp topicals; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Address: 2805 Place Louis-R Renaud, Laval, QC, Canada, H7V 0A3
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service